Devices and methods for modulating adma in blood
AssigneeThe Trustees of Indiana University
InventorJaipal SINGH
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for metabolically degrading ADMA. In one embodiment a device is provided for reducing a patients ADMA levels in their blood wherein the device comprises a biologically active dimethylarginine dimethylaminohydrolase (DDAH) polypeptide covalently linked to a solid support. In one embodiment a method for reducing ADMA levels in a patients blood comprises the step of contacting the patients blood or a blood fraction with an immobilized biologically active DDAH polypeptide, wherein contact of the patients blood with said DDAH polypeptide results in degradation of ADMA present in the patients blood.
Claims20
A device comprising:
- a biologically active dimethylarginine dimethylaminohydrolase (DDAH) polypeptide covalently or non-covalently linked to a solid support, wherein the solid support is porous and the DDAH polypeptide is immobilized on the surface of the solid support throughout the external and internal spaces of the solid support.
A blood treatment device comprising
- an arterial line;
- a blood pump;
- a blood treatment unit;
- and
- a venous line, wherein the arterial and venous lines can be connected to a blood vessel of a patient to form an extracorporeal blood circuit,
- wherein said blood treatment device comprises a biologically active dimethylarginine dimethylaminohydrolase (DDAH) polypeptide covalently linked to a solid support, and when said extracorporeal blood circuit is formed, said patient's blood flows through said blood treatment device and contacts said DDAH polypeptide before being returned to the patient.
A method of reducing ADMA levels in a patient's blood, said method comprising the step of
- passing said patient's blood or plasma through a column, said column comprising a particulate solid support having a biologically active DDAH polypeptide covalently linked to the surface of the solid support particles, wherein contact of the patient's blood or plasma with said DDAH polypeptide results in degradation of ADMA present in the patient's blood or plasma.
A method for reducing ADMA in patients on dialysis, in ICU and disease states including kidney disease, acute kidney injury, cardiac ischemia, heart failure, cardiomyopathry, sepsis, lung injury, preeclampia said method comprising the step of
- contacting the patient's blood or plasma with an immobilized biologically active DDAH polypeptide, ex vivo, wherein contact of the patient's blood or plasma with said DDAH polypeptide results in degradation of ADMA present in the patient's blood or plasma;
- and
- returning the contacted blood or plasma to the circulation of the patient.
Dependencies are inferred from the claim text.